Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-11-29
2005-11-29
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S469000, C548S483000, C544S336000, C544S373000, C546S201000, C514S415000
Reexamination Certificate
active
06969729
ABSTRACT:
The present invention relates to ion channel activating agents. More particularly, the present invention relates to a particular class of chemical compounds that has proven useful as openers of SKCa and IKCa channels. In further aspects, the present invention relates to the use of these SK/IK channel activating agents for the manufacture of medicaments and pharmaceutical compositions comprising the SK/IK channel activating agents. The SK/IK channel activating agents of the invention are useful for the treatment or alleviation of diseases and conditions associated with the SK/IK channels, in particular respiratory diseases such as asthma, cystic fibrosis, chronic obstructive pulmonary disease and rhinorrhea, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, urinary incontinence, bladder outflow obstruction, irritable bowel syndrome, gastrointestinal dysfunction, secretory diarrhea, ischaemia, cerebral ischaemia, ischaemic heart disease, angina pectoris, coronary heart disease, traumatic brain injury, psychosis, anxiety, depression, dementia, memory and attention deficits, Alzheimer's disease, dysmenorrhea, narcolepsy, Reynaud's disease, intermittent claudication, Sjorgren's syndrome, migraine, arrhythmia, hypertension, absence seizures, myotonic muscle dystrophia, xerostomi, diabetes type II, hyperinsulinemia, premature labor, baldness, cancer, and immune suppression.
REFERENCES:
patent: 4322533 (1982-03-01), Lesher et al.
patent: 4780477 (1988-10-01), Kobayashi et al.
patent: 5051417 (1991-09-01), Nadler et al.
patent: 5192792 (1993-03-01), Johnson
patent: 5312928 (1994-05-01), Goldin et al.
patent: 5565483 (1996-10-01), Hewawasam et al.
patent: 5602169 (1997-02-01), Hewawasam et al.
patent: 5952511 (1999-09-01), Esaki et al.
patent: 6114536 (2000-09-01), Esaki et al.
patent: 6797692 (2004-09-01), Ikonomidou
patent: 010 398 (1980-04-01), None
patent: 432 648 (1991-06-01), None
Garalene, Lab. Membrane Biophys. vol. 62, No. 3, pp. 20-24, (1999).
Buscarons et al. (1967) : Inform. Quim. Anal. (Madrid), 21 (6) , 191-201. STN International Caplus database, Columbus, Ohio, No. 69:27160, 1968.
Ahring Philip K.
Christophersen Palle
Jensen Bo Skaaning
Jørgensen Tino Dyhring
Olesen Søren Peter
Birch & Stewart Kolasch & Birch, LLP
Neurosearch A/S
Shameem Golam M. M.
LandOfFree
Use of isatin derivatives as ion channel activating agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of isatin derivatives as ion channel activating agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of isatin derivatives as ion channel activating agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3468226